Optimal treatment of early-stage ovarian cancer

Abstract

There is evidence of a long-term benefit of adjuvant post operative chemotherapy for early-stage ovarian cancer. The magnitude of benefit is greatest in patients at a higher risk of recurrence defined as stage 1B/1C grade 2/3, any stage 1 grade 3 or clear cell histology. The use of single agent carboplatin is recommended.

Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer

“…Recurrent disease was detected in 19% of the patients, which is consistent with the recurrence rates reported in other studies (10-30%) [6,7,13,25,26,27]. In the present study, adjuvant chemotherapy was not significantly associated with RFS and OS regardless of the staging procedure.…”

“…The 10-year results of the ICON1 study, which were published recently, showed an advantageous long-term effect of adjuvant chemotherapy in high-risk tumors [27]. …”

Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

“…In accordance with available data, 5,6 Danish guidelines suggest adjuvant chemotherapy to stage IA and IB serous carcinoma, grade 2/3 and all clear cell and all (1988) stage IC. 7 In the presented material, however, we did not have individual data on chemotherapy, but we assume that most IC1 patients received chemotherapy as recommended.…”

Effect of Chemotherapy on Health-Related Quality of Life among Early-Stage Ovarian Cancer Survivors: A Study from the Population-Based Profiles Registry

“…A switch of chemotherapy regimens from carboplatin-paclitaxel to pegylated liposomal doxorubicincarboplatin might reduce the toxicity 21 . Additionally, a reduction in the number of adjuvant chemotherapy cycles from 6 to 3 in patients with high-risk epithelial ovarian cancer did not result in a higher recurrence rate and was associated with reduced toxicity 6 .…”

“…Proper staging of presumed early-stage ovarian cancer is important starting point, because adjuvant chemotherapy could be withheld in many patients with early-stage disease 21,23 . Hence, adequate staging, specifically of patients with figo ia and ib disease, could avoid longterm side effects when chemotherapy is withheld in those patients.…”